Rate My Professor Oliver Bannard

Oliver Bannard is Professor of Adaptive Immunity at the MRC Weatherall Institute of Molecular Medicine, University of Oxford, within the Nuffield Department of Medicine. He holds a PhD from the University of Cambridge, completed in 2009 under the supervision of Professor Douglas Fearon. Following his doctorate, Bannard conducted postdoctoral research with Professor Jason Cyster at the University of California, San Francisco. He established his research group at the University of Oxford in 2015 as a group leader in the MRC Human Immunology Unit at the Weatherall Institute of Molecular Medicine, where he was appointed Sir Henry Dale Fellow and later Wellcome Senior Research Fellow. In 2025, he received a Wellcome Discovery Award to fund an eight-year research programme investigating how immune systems establish antibody-mediated immunity following vaccination and during infection.

Bannard's research centres on the mechanisms of adaptive immune responses, particularly the germinal centre reaction critical for antibody affinity maturation and B cell differentiation into plasma cells and memory B cells. His group explores cellular and molecular events driving competition between B cell clones, DNA mutagenesis, and selection processes in germinal centres to enhance vaccine-generated protective antibodies. Key publications include 'A double helix twist in HIV vaccine design' (Science, 2026, with M.R. Howarth); 'Germinal centers output clonally diverse plasma cell populations expressing high- and low-affinity antibodies' (Cell, 2023, with A. Sprumont et al.); 'Apoptotic cell fragments locally activate tingible body macrophages in the germinal center' (Cell, 2023, with A.K. Grootveld et al.); 'Secondary influenza challenge triggers resident memory B cell migration and rapid relocation to boost antibody secretion at infected sites' (Immunity, 2022, with A.J. MacLean et al.); and 'Competition for refueling rather than cyclic reentry initiation evident in germinal centers' (Science Immunology, 2022, with Z. Long et al.). His work, published in leading journals, advances understanding of humoral immunity and has implications for vaccine design and immunotherapy.